DYNLT1 promotes mitochondrial metabolism to fuel breast cancer development by inhibiting ubiquitination degradation of VDAC1

BACKGROUND: Mitochondrial metabolism has been proposed as an attractive target for breast cancer therapy. The discovery of new mechanisms underlying mitochondrial dysfunction will facilitate the development of new metabolic inhibitors to improve the clinical treatment of breast cancer patients. DYNL...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ling, Wei, Bo, Zhao, Yuran, Gong, Xue, Chen, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245490/
https://www.ncbi.nlm.nih.gov/pubmed/37280526
http://dx.doi.org/10.1186/s10020-023-00663-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245490/
https://www.ncbi.nlm.nih.gov/pubmed/37280526
http://dx.doi.org/10.1186/s10020-023-00663-0

Ejemplares similares